Image Name

Jiangsu Vcare Secures Nearly CNY 200 Million in Series C+ Financing




Related News

04

2024

/

01

Jiangsu Vcare's Next-Generation TRK Inhibitor VC004 Completes First Patient Enrollment in China's Pivotal Phase II Trial

Recently, Jiangsu Vcare Pharmaceutical Technology Co., Ltd. (Jiangsu Vcare) completed the first patient enrollment in the pivotal Phase II clinical trial (Registration Number: CTR20201703) in China for its self-developed next-generation TRK inhibitor, VC004. This clinical trial aims to further evaluate the efficacy and safety of VC004 in treating patients with NTRK gene fusion mutations.


View Details

02

2024

/

01

Jiangsu Vcare Secures Over CNY 450 Million in Series C Funding

Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series C financing round, raising over CNY 450 million. The investment consortium included China Life Private Equity Investment, DYEE Capital, Hongyao Technology Capital, existing investor Nanjing Innovation Capital Group, and Hangzhou Huadian Investment.


View Details

13

2023

/

12

Jiangsu Vcare Approved to Establish "Provincial-Level Enterprise Technology Center"

Recently, the Jiangsu Provincial Department of Industry and Information Technology released the list of enterprises proposed for recognition as 2023 Provincial-Level Enterprise Technology Centers. Jiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) has been recognized as a"2023 Provincial-Level Enterprise Technology Center".


View Details

10

2023

/

11

Jiangsu Vcare's Next-Generation TRK Inhibitor VC004 Enters Pivotal Phase II Trial

Recently, the initiation of the pivotal Phase II trial for Jiangsu Vcare Pharmaceutical Technology Co., Ltd.'s (Jiangsu Vcare) next-generation TRK inhibitor VC004 project was announced at its first center, the Cancer Hospital Chinese Academy of Medical Sciences. Subsequent recruitment will take place across nearly 30 clinical centers nationwide.


View Details

01

2023

/

11

Jiangsu Vcare's Next-Generation TRK Inhibitor VC004 Project Approved for Pivotal Phase II Clinical Trial

Recently, the pivotal Phase II clinical study for Jiangsu Vcare Pharmaceutical Technology Co., Ltd.'s (Jiangsu Vcare) next-generation TRK inhibitor VC004 for treating NTRK fusion-positive solid tumors was approved by the NMPA. This clinical study will further evaluate the efficacy and safety of VC004 in patients with NTRK fusion mutations. Upon success, Jiangsu Vcare plans to submit an NDA in China.


View Details

11

2023

/

08

Jiangsu Vcare's Second-Generation Selective JAK1 Inhibitor VC005 Topical Gel Completes First Patient Dosing in Mild-to-Moderate Atopic Dermatitis Trial

Recently, the second-generation selective JAK1 inhibitor VC005 Topical Gel, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), completed the first topical skin dosing in a patient with mild-to-moderate atopic dermatitis(AD).


View Details

< 1...101112...16 > proceed page